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Abstract
Purpose This study evaluated mechanistic diVerences of
pralatrexate, methotrexate, and pemetrexed.
Methods Inhibition of dihydrofolate reductase (DHFR)
was quantiWed using recombinant human DHFR. Cellular
uptake and folylpolyglutamate synthetase (FPGS) activity
were determined using radiolabeled pralatrexate, metho-
trexate, and pemetrexed in NCI-H460 non-small cell lung
cancer (NSCLC) cells. The tumor growth inhibition (TGI)
was assessed using MV522 and NCI-H460 human NSCLC
xenografts.
Results Apparent Ki values for DHFR inhibition were 45,
26, and >200 nM for pralatrexate, methotrexate, and
pemetrexed, respectively. A signiWcantly greater percent-
age of radiolabeled pralatrexate entered the cells and was
polyglutamylatated relative to methotrexate or pemetrexed.
In vivo, pralatrexate showed superior anti-tumor activity in
both NSCLC models, with more eVective dose-dependent
TGI in the more rapidly growing NCI-H460 xenografts.
Conclusions Pralatrexate demonstrated a distinct mecha-
nistic and anti-tumor activity proWle relative to methotrex-
ate and pemetrexed. Pralatrexate exhibited enhanced
cellular uptake and increased polyglutamylation, which
correlated with increased TGI in NSCLC xenograft models.
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Introduction
Folate plays a key role in the one-carbon metabolic pro-
cesses essential for deoxyribonucleic acid (DNA) replica-
tion. Antifolates are divalent anions which cross the cell
membrane predominantly via the reduced folate carrier
(RFC-1). RFC-1 is an oncofetoprotein found predominantly
in the membranes of fetal and tumor cells [1]. Upon entry
in the cell, antifolates are polyglutamylated by folylpolyg-
lutamate synthetase (FPGS), and the polyglutamylated
products tend to be retained within the cell. Polyglutamyla-
tion is a time- and concentration-dependent process that
occurs in tumor cells and to a lesser extent in normal tis-
sues. The longer intracellular half-life of these polygluta-
mylated conjugates extends product action in malignant
cells through more eVective dihydrofolate reductase
(DHFR) inhibition [2, 3]. Because the intracellular concen-
tration of antifolates is critical for their pharmacological
activity, polyglutamylation is a key determinant of antifo-
late-mediated cytotoxicity [4].
Methotrexate was designed nearly 60 years ago and
functions to block the activity of DHFR. Methotrexate is
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approved for use in the treatment of gestational choriocarci-
noma, chorioadenoma destruens and hydatidiform mole. In
acute lymphocytic leukemia, methotrexate is approved for
the prophylaxis of meningeal leukemia and is used in main-
tenance therapy in combination with other chemotherapeu-
tic agents. Methotrexate is used alone or in combination
with other anticancer agents in the treatment of breast can-
cer, head and neck cancer, bladder cancer, advanced myco-
sis fungoides, and lung cancer, particularly squamous cell
and small cell types. Methotrexate is also used in combina-
tion with other chemotherapeutic agents in the treatment of
advanced stage non-Hodgkin’s lymphomas. More recently
investigated antifolates include raltitrexed (Tomudex®) and
pemetrexed (Alimta®) which target thymidylate synthase
(TS) and glycinamide ribonucleotide formyl transferase
(GARFT). Alimta® is approved for the treatment of non-
small cell lung cancer (NSCLC) and malignant pleural
mesothelioma. Methotrexate has also been used extensively
for treatment of certain autoimmune disorders, primarily
rheumatoid arthritis [5–7].
Pralatrexate [PDX (RS)-10-propargyl-10-deazaaminop-
terin], is a 10-deazaaminopterin analog of methotrexate,
and is a small-molecule inhibitor of DHFR (Fig. 1). Pralat-
rexate diVers from methotrexate at position 10 where a car-
bon with a propargyl side chain is substituted for the
nitrogen with a methyl substituent. Pralatrexate was ratio-
nally designed for improved cellular transport via RFC-1,
and to have greater intracellular drug retention through the
enhanced formation of polyglutamylated conjugates [2, 3].
The relative diVerence in polyglutamate formation in nor-
mal versus malignant cells may account for the enhanced
pharmacodynamic activity of pralatrexate. Pralatrexate is
thought to exert its pharmacological eVect primarily
through inhibition of DHFR, having an IC50 in the picomo-
lar range [8].
This study investigated the potential mechanistic diVer-
ences between pralatrexate and other antifolates, speciW-
cally methotrexate and pemetrexed. Despite being
introduced over 40 years ago, methotrexate is still used
today in the treatment of several tumor types; however, few
methotrexate analogues have been developed. In compari-
son to methotrexate, pralatrexate has demonstrated superior
in vitro and in vivo anti-tumor activity in breast and lung
cancer cell lines and in xenograft models of lymphoma [9,
10], human mammary carcinoma, and NSCLC [8]. Pralat-
rexate has been studied in three completed [11–13] and two
ongoing clinical trials in NSCLC, and one completed study
in mesothelioma [14]. In a Phase 2 study in NSCLC, the
median time to progression of disease for patients who
achieved stable disease and for those with a partial response
(PR) was ¸10.5 months. The median duration of survival
was 13 months [13]. Furthermore, four clinical trials are
ongoing in lymphoma. Preliminary data from one of the
ongoing studies have shown responses in 14 of 26 (54%)
evaluable patients with T cell lymphoma, of which nine
were complete responses (CR) [15].
Materials and methods
Reagents
Drugs used included [14C]-pralatrexate, 28.4 mCi/mmol,
4.58 M (Clauson-Kaas A/S, Farum, Denmark); [3H]-
methotrexate, 49.6 Ci/mmol, 20.16 M (Moravek, Brea,
CA); [14C]-pemetrexed, 51.7 mCi/mmol, 5.55 M (Eagl-
ePicher Pharmaceutical Services, LLC, Lenexa, KA); pra-
latrexate (Pharmaceutical Service, University of Iowa,
Iowa City, IA), methotrexate (Sigma-Aldrich, St Louis,
MO), and pemetrexed (Eli Lilly, Indianapolis, IN).
In vitro studies
NCI-H460 human NSCLC cells obtained from the Ameri-
can Type Cell Collection, Manassas, VA, were propagated
in vitro as described [16]. MV522 human metastatic human
NSCLC cells were obtained from Dr. M.J. Kelner (Univer-
sity of California, San Diego) and propagated as described
[16].
Enzyme activity assays
DHFR activity was determined using a spectrophotometric
assay that measured the decrease of absorbance at 340 nm
Fig. 1 Pralatrexate and methotrexate structures
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characteristic of dihydrofolate as it is reduced to tetrahydro-
folate (THF) [17] using a DHFR activity assay kit (Sigma-
Aldrich, St Louis, MO). The experiments were repeated at
least twice. Apparent inhibition constants (Ki app) were
determined using the INTERCEPT function (Microsoft
Excel). To measure folylpolyglutamyl synthetase (FPGS)
activity, we Wrst optimized a conventional FPGS assay that
used [14C]-L-glutamic acid as a substrate for glutamylation
[18] using archived tumor tissue xenografts from the in
vivo study. Tumor tissue was processed as described [19].
FPGS activity was assayed at 37°C for 60 min in the pres-
ence of 1 mM L-glutamate, 5 mM MgATP, and 500 M
aminopterin. The reaction was terminated by boiling the
samples for 3 min. The samples were chilled on ice and
centrifuged. Product and substrates were separated after
spotting onto PEI-cellulose thin-layer chromatography
(TLC) sheets and chromatography, with 0.5% (w/v) NH4Cl
and 0.5% (v/v) -mercaptoethanol as eluents. TLC sheets
were dried, individual lanes corresponding to discrete sam-
ples were cut out and further dissected into 0.5 cm sections.
The sections were placed in Ready-Gel (Beckman, Fuller-
ton, CA) and counted on a Beckman LS6500.
The above assay was modiWed to measure FPGS activity
in NCI-H460 cells using radiolabeled drugs [14C-(pralatrex-
ate or pemetrexed) or 3H-methotrexate] as the substrates for
glutamylation. BrieXy, NCI-H460 cells in the logarithmic
growth phase were counted and plated in 12-well plates at a
density of 500,000 cells per treatment group (all treatments
in duplicate). The cells were incubated at 37°C for 15 or
60 min with (a) radiolabeled pralatrexate, methotrexate, or
pemetrexed at 2 M  Wnal concentration each [speciWc
activity of radiolabeled drugs was 56 Ci/mL (pralatrex-
ate), 95 Ci/mL (methotrexate), and 103 Ci/mL (pemetr-
exed)], (b) radiolabeled pralatrexate, methotrexate, or
pemetrexed at 2 M Wnal concentration each plus 1 mM
(500-fold molar excess) of the unlabeled respective drugs,
or (c) vehicle. Following the incubation, the cell pellets
were washed twice with ice-cold HEPES-buVered saline, to
remove free radiolabeled drugs that were not taken up by
the cells. The cells were then resuspended in water and
lysed by sonication on ice followed by centrifugation at
14,000g for 15 min. Product and substrates were separated
by TLC and the incorporated radioactivity was measured
by liquid scintillation counting (LSC) as described above.
In vivo xenograft studies
Female nude mice (nu/nu) between 5 and 6 weeks of age
weighing approximately 20 g were obtained from Harlan
Inc. (Madison, WI). Fragments of NCI-H460 or MV522
harvested from tumors grown subcutaneously (SC) in
host animals were implanted SC by trocar into the right
Xank of the nu/nu mice. When the tumors had grown to
approximately 100 mm3 in size, animals were paired by
tumor size into treatment and control groups; each group
contained nine mice. The antifolates were administered as
single agents via intraperitoneal (IP) injection. Pralatrexate
was dosed at 1 and 2 mg/kg [every day (QD) £ 5, for two
cycles of 5 days each]. Other treatments included pemetr-
exed (150 mg/kg; QD £ 5, for two cycles) and methotrex-
ate (1 and 2 mg/kg; QD £ 5, for two cycles). Equivalent
doses of the two antifolates were chosen as there were no
previous data available in this murine model. SigniWcant
endpoints included mean tumor growth inhibition (TGI),
weight loss, and treatment toxicity determined as described
[19]. Principles of laboratory animal care per NIH publica-
tion 85–23 (revised 1985) were followed in all animal
experiments.
Results
To evaluate the relative potency of the three drugs as
DHFR inhibitors, the inhibitory activity of pralatrexate in a
cell-free system against recombinant human DHFR was
compared to the inhibitory activities of methotrexate and
pemetrexed. Initial velocities of the DHFR enzymatic reac-
tion were measured in the presence and absence of pralat-
rexate. The results showed clear concentration-dependent
inhibition of activity by pralatrexate (Fig. 2a). Similar pat-
terns of concentration-dependent inhibition were observed
with methotrexate and pemetrexed (data not shown). Plots
of the initial velocities were used to calculate apparent inhi-
bition constants (Ki app) of DHFR inhibition by the antifo-
lates. Respective Ki app values were 45 nM and 26 nM for
pralatrexate (Fig. 2b) and methotrexate (Fig. 2c). Pemetr-
exed was a weak inhibitor of DHFR relative to pralatrexate
and methotrexate; only 40% relative inhibition was
observed at 200 nM pemetrexed (Fig. 2d).
The biological activity of many clinically useful antifo-
lates is directly related to the intracellular concentration of
polyglutamylated species of the drug produced by the
action of FPGS [20]. Since pralatrexate, methotrexate, and
pemetrexed are substrates for FPGS, we hypothesized that
their biological activity may be related to the extent of
polyglutamylation and the resultant increase in concentra-
tion of the polyglutamylated derivatives in cancer cells.
In our preliminary experiments we have demonstrated
using a standard FPGS assay [18] that non-polyglutamy-
lated drugs had distinctly diVerent TLC mobilities relative
to the polyglutamylated derivatives (data not shown).
Based on these results, which were consistent with an
earlier report [18], we anticipated that the radiolabeled
polyglutamylated products could be separated from the
unreacted 14C-labeled glutamate (retention factor Rf =0 . 6 )
by standard TLC methods.996 Cancer Chemother Pharmacol (2009) 64:993–999
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To test this hypothesis, we modiWed a conventional
FPGS activity assay, which employed radiolabeled L-gluta-
mate and unlabeled antifolates as substrates, and substituted
them with unlabeled L-glutamate and radiolabeled antifo-
lates instead. Given that the radiolabeled polyglutamylated
products would have diVerent mobilities compared to that
of non-glutamylated substrates, these species could be
resolved using TLC. Our modiWed in vitro assay used radi-
olabeled pralatrexate, methotrexate, and pemetrexed and
unlabeled L-glutamate to compare the short-term uptake of
radiolabeled antifolates in NCI-H460 cells. The drugs were
incubated with the cells for either 15 or 60 min in two regi-
mens; (a) radiolabeled drug alone, or (b) radiolabeled agent
plus 500-fold molar excess of the unlabeled drugs.
As illustrated in Fig. 3, the radiolabel was detectable in
species of low mobility (Rf < 0.2; TLC sections 1 and 2 corre-
sponding to free drugs) and high mobility (Rf >0 . 5 ;  T L C
sections 7–12; presumably the high mobility species were
polyglutamylated drug species). The background radioactivity
was similar for all drugs. Given that the same total number of
cells was used for each drug treatment, the results are normal-
ized per total protein content. The higher background radioac-
tivity observed for methotrexate was due to a radio-impurity
in the preparation of the labeled compound. The total uptake
of radiolabeled drugs, which was measured at 15 and 60 min,
was similar at both times for methotrexate and decreased over
time for pemetrexed. Greater radiolabel uptake was only
observed with pralatrexate at 60 min. A signiWcantly smaller
molar fraction of radiolabeled methotrexate and pemetrexed
entered the cells relative to the absorbed molar fraction of pra-
latrexate. Radiolabeled species (polyglutamylated pralatrex-
ate) having greater Rf values than pralatrexate alone in a cell-
free system (Rf > 0.5) appeared in a time-dependent manner in
pralatrexate-treated cell extracts. Pemetrexed was polyg-
lutamylatated to a lesser extent than was pralatrexate. No
polyglutamylated forms of methotrexate could be observed.
Only in the case of pralatrexate was a drug-speciWc increase in
polyglutamylated species observed because only for pralat-
rexate was the increase in polyglutamylated species signiW-
cantly mitigated (>84%) by the addition of excess unlabeled
drug. Notably, because the speciWc radioactivity of pralatrex-
ate was approximately twofold lower than that of methotrex-
ate or pralatrexate, these data are likely to underestimate the
extent of polyglutamylation by pralatrexate.
To compare relative potencies and antitumor activities of
the antifolates, their in vivo activity was measured in a pilot
study using two human NSCLC models, MV522 and NCI-
H460, with TGI as the primary eYcacy endpoint (Fig. 4a).
In MV522, high-dose pralatrexate treatment resulted in
treatment-related toxicity, as determined by signiWcant
weight loss in some animals prior to death; however,
remaining mice regained all lost weight by Day 35
(Fig. 4b). TGI (38%) was observed in the 2 mg/kg pralat-
rexate-treated group, indicating activity in this model,
although pralatrexate was not considered active in this model
according to NCI standards (TGI > 58%). Pralatrexate was
Fig. 2 Inhibition of DHFR activity by pralatrexate in a cell-free sys-
tem. a Concentration dependence of DHFR activity. b–d Estimation
of  Ki app for DHFR inhibition by pralatrexate, methotrexate, and
pemetrexed, respectively
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superior to methotrexate and pemetrexed at the evaluated
doses in this model. However, the TGI value calculated for
pralatrexate was based on results from only four animals,
limiting more concrete comparison of the groups. Overall,
the results from the remaining animals demonstrated
increased antitumor activity with pralatrexate in the MV522
model compared to methotrexate and pemetrexed.
In NCI-H460 (Fig. 4b), single-agent pralatrexate treatment
resulted in dose-dependent weight loss, which the animals
had not recovered from by study completion. Aggressive
tumor growth prevented further analysis of possible weight
recovery in this group. TGI was reported in groups dosed with
1 (34%) or 2 (52%) mg/kg pralatrexate (Fig. 4a). While nei-
ther dose group met the NCI criteria for an active agent
(TGI > 58%), TGI in the 2 mg/kg group reached statistical
signiWcance (P < 0.05) versus control, indicating activity in
this model. In a direct comparison, pralatrexate was superior
to either dose of methotrexate (1 and 2 mg/kg), and pemetr-
exed (150 mg/kg) was inactive in this model. Overall, pralat-
rexate demonstrated dose-dependent antitumor activity in the
NCI-H460 model and demonstrated greater activity than
methotrexate at the same dose-treatment schedule.
Fig. 3 A short-term uptake of radiolabeled antifolates in NCI-H460 cells Drugs were dosed for 15 or 60 min. White bars cells incubated with
radiolabeled drug only, black bars cells incubated with radiolabeled drug plus excess unlabeled drug
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Discussion
This study reports a head-to-head comparison of in vitro
and in vivo activities of three antifolates: pralatrexate,
methotrexate, and pemetrexed. A clear diVerence was dem-
onstrated among the antifolates in regulation of enzymatic
activity. Pralatrexate demonstrated a unique activity proWle
relative to methotrexate and pemetrexed. The in vitro
mechanistic diVerences were established through enhanced
cellular uptake and intracellular polyglutamylation of
pralatrexate, correlating with more eVective TGI by pralat-
rexate in two NSCLC xenograft models in vivo compared
to methotrexate or pemetrexed. Unlike pralatrexate, the
activities of methotrexate and pemetrexed were found to be
model-dependent. Interestingly, however, a greater degree
of dose-dependent eVect of pralatrexate on TGI was
observed in the more rapidly growing NCI-H460 xenograft
model.
The observation of enhanced polyglutamylation of pra-
latrexate in human cancer cells suggests that pralatrexate
may overcome some of the limitations associated with
antifolate resistance, which represents a major challenge in
cancer chemotherapy with agents of this class. The most
common mechanisms of antifolate resistance are associated
with qualitative and/or quantitative alterations in inXux or
eZux transport of antifolates [4], and in some instances,
mutations in folate-dependent enzymes [21, 22]. The pre-
dominant mechanism of resistance to many antifolates
including methotrexate and pemetrexed, is impaired poly-
glutamylation due to signiWcantly decreased FPGS activity.
Multifunctional mechanisms of resistance in cancer cells
have a diVerential impact on cellular folate homeostasis
including decreased polyglutamylation and transport
defects that lead to folate depletion [23].
The mechanisms of antifolate sensitivity are almost cer-
tainly more complex than has heretofore been appreciated.
The eVects of FPGS modulation on the chemosensitivity of
human cancer cells to methotrexate depend not only on
polyglutamylation of a speciWc target intracellular folate
cofactor or methotrexate, but also on total intracellular
folate pools and polyglutamylation of other intracellular
substrates. It remains to be determined whether FPGS mod-
ulation is a relevant index of chemosensitivity of cancer
cells to methotrexate [24]. Pralatrexate diVers from other
antifolates both structurally and mechanistically, which has
been demonstrated in this study to translate into diVerences
in anti-tumor activity.
This study conWrms previous observations of
enhanced intracellular drug retention and formation of
polyglutamylated metabolites of pralatrexate relative to
other antifolates [2, 3]. These polyglutamylated metabo-
lites have a prolonged intracellular half-life and allow for
extended drug action in malignant cells and more eVec-
tive DHFR inhibition by the polyglutamylated forms [2,
3]. The relative diVerences in observed polyglutamate
adduct formation in normal versus malignant cells may
account for the enhanced pharmacodynamic activity of
pralatrexate.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
Fig. 4 DiVerential activity of the antifolates on tumor volume and
body weight in NCI-H460 and MV522 human tumor xenografts. a Per-
cent change in tumor volume. b Percent change in total body weight.
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